Cantor Fitzgerald Starts Flex Pharma (FLKS) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
JMP Securities Starts Flex Pharma (FLKS) at Market Outperform
February 23, 2015 7:34 AM ESTJMP Securities initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Market Outperform rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreRoth Capital Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:33 AM ESTRoth Capital initiated coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $27.00.
For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.
Shares of Flex Pharma closed at $14.71 yesterday.
... MoreJefferies Starts Flex Pharma (FLKS) at Buy
February 23, 2015 7:15 AM ESTJefferies initiates coverage on Flex Pharma (NASDAQ: FLKS) with a Buy rating and a price target of $25.00.
Analyst Ryan Martins comments, "FLKS' proprietary formulation of transient receptor potential (TRP) ion channel activators is well positioned to address muscle cramps and other neuromuscular... More
Piper Jaffray Starts Flex Pharma (FLKS) at Overweight; Sees ~70% Upside
February 23, 2015 6:50 AM ESTPiper Jaffray initiates coverage on recent IPO Flex Pharma (NASDAQ: FLKS) with a Overweight rating and a price target of $25.00.
Analyst Joshua Schimmer commented, "We are initiating coverage of Flex Pharma with an OW rating and $25 PT, representing ~70% upside from... More
